ArticleActa pharmaceutica Sinica. B2026
Bladder adaptive hydrogel scaffold with dual release, antimicrobial, immunomodulatory, and repair: DRIVER for urinary tract infections.
Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional hydrogel biomaterials for urological diagnosis and treatment-design strategies and application progress: a review.Journal of materials science. Materials in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs), especially complex or recurrent cases, present a significant challenge. Systemic antibiotics often fail to provide adequate local drug concentrations, leading to limited efficacy and relapse. Local delivery is hindered by the bladder's dynamic environment, causing rapid drug clearance. To address this, a hydrogel scaffold, DRIVER (dual release, repair of tissues, immunomodulation, vesical adaptation, elimination of pathogens, and regulation of autophagy), is designed for sustained release in sync with the infection cycle. DRIVER forms a self-regulating 3D network through dynamic bonding and metal ion coordination, ensuring stable release and adaptability. It delivers a biphasic release profile comprising an initial antimicrobial burst that rapidly suppresses acute infection, followed by a 7-day sustained release phase.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.